Medical Oncology

Thyroid Cancer   

Questions discussed in this category

How would you approach patient with metastatic anaplastic thyroid cancer with NGS revealing only ARID1A mutation?
1 Answer available
Would you offer, and what data would support, the use of an FGFR inhibitor in FGFR3 mutated anaplastic thyroid cancer?
1 Answer available
What treatment would you initiate post-operatively for patients with de novo metastatic follicular thyroid CA requiring laminectomy for cord compression?
In addition to TSH suppression, would you opt for RAI, targeted treatment based off NGS, or lenvatinib?
1 Answer available
Is there any contraindication to concurrent administration of radioactive iodine in a patient on immunotherapy?
A patient with stage 3 melanoma on adjuvant nivolumab needs radioactive iodine for papillary thyroid cancer.
1 Answer available
For patients with metastatic radioctive iodine refractory papillary thyroid carcinoma that is BRAF V600E mutant and rapidly progressive, would you consider dabrafenib/trametinib combo instead of lenvantinib or sorafenib first line?
Aggressive histology with tall cell variant papillary thyroid carcinoma that's progressed 2 months after RAI and while on TSH suppression, without tra...
1 Answer available
Do you prefer rhTSH for TSH stimulation instead of thyroid hormone withdrawal when treating patients with radioactive iodine for papillary thyroid carcinoma?
If not, what is your thyroid hormone withdrawal protocol?  If so, would you still treat a patient with possibly metastatic disease?  
1 Answer available


Papers discussed in this category

N. Engl. J. Med., 2012-05-03
Strategies of radioiodine ablation in patients with low-risk thyroid cancer.
N. Engl. J. Med., 2012-05-03
Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer.
The New England journal of medicine, 2015-02-12
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Cancer discovery, 2015-07
ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.
J Immunother Cancer,
alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy.

Related Topics in Medical Oncology

Copyright © 2021 theMednet
All Rights Reserved.